Drug intelligence / Profile preview

Multigen + cholecystokinin

Development stage
Unknown
Lead developer
MAIA Pharmaceuticals
Modality
Peptides, Small Molecules
Administration
Oral, Intravenous
01

Overview

Multigen + cholecystokinin is not a recognized fixed-dose combination or co-packaged pharmaceutical product. **Multigen** is a brand name for a prescription hematinic supplement typically containing ferrous fumarate (iron), cyanocobalamin (vitamin B12), and folic acid, indicated for the treatment of iron-deficiency anemias and associated nutritional deficiencies. **Cholecystokinin** (CCK) is a gastrointestinal peptide hormone that stimulates gallbladder contraction and pancreatic enzyme secretion. In clinical practice, synthetic analogs of CCK, such as sincalide (Kinevac), are used as diagnostic agents to evaluate gallbladder and pancreatic function during imaging procedures like hepatobiliary (HIDA) scans. There is no established therapeutic or diagnostic rationale for combining a daily oral iron supplement with an injectable gastrointestinal hormone into a single drug product, and no such product is verified in clinical pipelines or regulatory databases.

Other names
ferrous fumarate + cyanocobalamin + folic acid + cholecystokinin
02

Targets

CCKAR (Cholecystokinin A receptor)

Beyond the preview

Go deeper on Multigen + cholecystokinin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multigen + cholecystokinin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call